Home LiteratureArticle Details
PMID: 8529284 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.

Cancer chemotherapy and pharmacology ·Vol. 37 ·No. 3 ·1996-00-00 ·Pages 242-46

Dong Q, Bullock N, Ali-Osman F, Colvin OM, Bigner DD, Friedman HS

Abstract

Cyclophosphamide is one of the most active agents in the treatment of medulloblastoma. However, development of resistance to this alkylator frequently occurs and is the harbinger of tumor progression and death. In order to understand the biochemical basis of this resistance, we generated a panel of medulloblastoma cell lines in our laboratory that were resistant to 4-hydroperoxycyclophosphamide (4-HC). Previously, we have shown that elevated levels of aldehyde dehydrogenase and glutathione mediate cellular resistance to 4-HC. The present study was conducted to identify the third unknown mechanism mediating the resistance of cell line D283 Med (4-HCR) to 4-HC, testing the hypothesis that this resistance is mediated by an increased repair of DNA interstrand crosslinks (ICLs). The doses of 4-HC that produced a one- and two-log cell kill of D283 Med cells were 25 and 50 microM, respectively, compared with values of 125 and 165 microM in D283 Med (4-HCR), the resistant cell line. The formation and disappearance of 4-HC-induced DNA ICLs at the c-myc gene were subsequently studied by DNA denaturing/renaturing gel electrophoresis and Southern blot analysis. 4-HC-induced DNA ICLs in the c-myc gene exhibited a dose-dependent relationship. The percentage of the c-myc gene that was crosslinked was approximately 1-3% at a dose of 100 microM. More than 50% of the DNA crosslinking in D283 Med (4-HCR) cells was removed by 6 h after drug treatment, whereas, in D283 Med cells, more than 90% of the DNA crosslinking was still present at 6 h. These findings suggest that the increased repair of DNA ICLs in D283 Med (4-HCR) may contribute significantly to its resistance to 4-HC.

MeSH Terms
Blotting, Southern Cross-Linking Reagents/pharmacology Cyclophosphamide/analogs & derivatives,pharmacology DNA, Neoplasm/drug effects Drug Resistance, Neoplasm Electrophoresis Genes, myc/drug effects Humans Medulloblastoma/drug therapy,genetics,physiopathology Tumor Cells, Cultured
Chemicals
Cross-Linking Reagents DNA, Neoplasm Cyclophosphamide perfosfamide
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Dong Q
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Bullock N
Ali-Osman F
Colvin O M
Bigner D D
Friedman H S
References (28)
28 references, click to expand
  1. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.
    J Neurosurg. 1981 Nov;55(5):749-56 PMID: 7310496
  2. Alkylating properties of phosphoramide mustard.
    Cancer Res. 1976 Mar;36(3):1121-6 PMID: 1253171
  3. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
    Cancer Res. 1988 Oct 1;48(19):5397-402 PMID: 3416297
  4. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial.
    Cancer. 1983 Dec 1;52(11):2001-6 PMID: 6627214
  5. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.
    J Neuropathol Exp Neurol. 1985 Nov;44(6):592-605 PMID: 4056828
  6. Cyclophosphamide resistance in medulloblastoma.
    Cancer Res. 1992 Oct 1;52(19):5373-8 PMID: 1356617
  7. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review.
    Cancer Res. 1990 Oct 15;50(20):6449-54 PMID: 2208103
  8. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
    Mol Cell Biol. 1992 Sep;12(9):3689-98 PMID: 1380646
  9. Processing of psoralen adducts in an active human gene: repair and replication of DNA containing monoadducts and interstrand cross-links.
    Cell. 1987 Aug 28;50(5):789-99 PMID: 3621344
  10. Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells.
    J Biol Chem. 1987 Nov 5;262(31):15048-53 PMID: 3667623
  11. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.
    Cancer Res. 1990 Apr 15;50(8):2347-50 PMID: 2180567
  12. Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR.
    Cell Growth Differ. 1992 Apr;3(4):217-23 PMID: 1515367
  13. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.
    Cancer Chemother Pharmacol. 1993;32(2):85-9 PMID: 8485812
  14. Heterogeneous DNA damage and repair in the mammalian genome.
    Cancer Res. 1987 Dec 15;47(24 Pt 1):6426-36 PMID: 3315187
  15. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
    Cancer Res. 1993 Dec 1;53(23):5663-8 PMID: 8242621
  16. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.
    Cancer Res. 1984 Nov;44(11):5156-60 PMID: 6488175
  17. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential.
    J Biol Chem. 1993 Feb 5;268(4):2649-54 PMID: 8428941
  18. Transport of melphalan by sensitive and resistant L1210 cells.
    Cancer Res. 1980 Apr;40(4):1144-9 PMID: 7357545
  19. Alkylating agent resistance: in vitro studies with human cell lines.
    Proc Natl Acad Sci U S A. 1985 Apr;82(7):2158-62 PMID: 3856890
  20. A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro.
    Cancer Chemother Pharmacol. 1986;17(3):223-6 PMID: 3742706
  21. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Cancer Res. 1986 Sep;46(9):4379-83 PMID: 3731096
  22. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells.
    Biochem Pharmacol. 1984 Jun 15;33(12):1867-72 PMID: 6732847
  23. Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.
    Neurosurgery. 1986 Mar;18(3):335-40 PMID: 3703192
  24. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide.
    Prog Clin Biol Res. 1989;290:65-79 PMID: 2726824
  25. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.
    Cancer Res. 1990 May 1;50(9):2549-53 PMID: 2158392
  26. Metabolism of oxazaphosphorines.
    Pharmacol Ther. 1988;37(3):301-55 PMID: 3290910
  27. Pharmacology of cyclophosphamide and metabolites.
    Cancer Treat Rep. 1981;65 Suppl 3:89-95 PMID: 7049370
  28. Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anemia patients.
    Mutat Res. 1989 May;217(3):185-92 PMID: 2497343
Article Info
Journal
Cancer chemotherapy and pharmacology
Abbr.
Cancer Chemother Pharmacol
ISSN
0344-5704
Published
1996-00-00
Pages
242-46
Language
English
Region
Germany
NLM ID
7806519
Subset
IM
Grants
NCI NIH HHS · CA 11898 · United States
NCI NIH HHS · CA 56115 · United States
NINDS NIH HHS · NS 30245 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]